Table 2.
BTK inhibitors COVID-19 randomized clinical trials information.
| Trial Identifier/Status | Sponsor | Population | Intervention | Control Group | Primary Outcome |
|---|---|---|---|---|---|
| NCT04380688 (phase II, completed) | AstraZeneca | N = 62 | Acalabrutinib (orally) | Best supportive care | Serious adverse events, death, and respiratory failure |
| NCT04346199 (phase II, completed) | AstraZeneca | N = 177 | Acalabrutinib (orally) | Best supportive care | Death and respiratory failure |
| NCT04647669 (phase III, not yet recruiting) | The University of The West Indies | N = 100 | Acalabrutinib (orally)/remdesivir (IV)/Interferon beta-1a (IV) | Local standard of care | Mortality rate |
| NCT05024006 (phase: Not Applicable, completed) | University of the Philippines | N = 1314 | Acalabrutinib (orally) but not limited to it | Local standard of care | Mortality rate |
| NCT04375397 (phase II, completed) | AbbVie | N = 46 | Ibrutinib (orally) | Placebo | Death and respiratory failure |
| NCT04439006 (phase II, active, not recruiting) | Jennifer Woyach | N = 10 | Ibrutinib (orally) | Usual care | Death, respiratory failure |
| NCT04382586 (phase II, completed) | BeiGene | N = 63 | Zanubrutinib (orally) + supportive care | Supportive care + placebo | Respiratory failure and time to breathe room air |